Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 8/20 | 1.00 |
| ▸ | HTR1D | P28221 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 12/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103416 | 1.00 | HTR1B (1.00) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL29391208 | 1.00 | HTR1B (1.00) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8790026 | 0.97 | HTR1B (0.94) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8790021 | 0.97 | HTR1B (0.94) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| Fumaric Acid SCHEMBL7834727 | 0.93 | HTR1B (0.86) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| Fumaric Acid SCHEMBL7834732 | 0.93 | HTR1B (0.86) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| Fumaric Acid SCHEMBL7834729 | 0.93 | HTR1B (0.86) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8789303 | 0.91 | HTR1B (0.83) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8789309 | 0.91 | HTR1B (0.83) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL9079373 | 0.91 | HTR1B (0.83) | HTR1BHTR1DHTR1ACHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| CN-114599355-A | Method for treating psychological and cerebral diseases | 马里兰大学巴尔的摩分校 | 2022-06-07 | — | — | CN | claimed |
| CN-1509713-A | Indole derivative use as 5HT1 antagonist agent | — | 2004-07-07 | — | — | CN | claimed |
| EP-0696194-B1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER (US) | 2002-08-21 | — | — | EP | claimed |
| EP-0827503-B1 | PYRROLIDINYL METHYL INDOLE SALT | PFIZER RES & DEV (IE) | 2000-07-26 | — | — | EP | claimed |
| US-5994387-A | MIGRAINE THERAPY | PFIZER INC. (US) | 1999-11-30 | — | — | US | claimed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | claimed |
| US-5618834-A | Indole derivatives in the treatment of emesis | PFIZER INC. (US) | 1997-04-08 | — | — | US | claimed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | claimed |
| EP-0714659-A2 | Indole derivatives in the treatment of emesis | Pfizer Limited (GB) | 1996-06-05 | — | — | EP | claimed |
| CN-1121689-A | Use of indole derivatives as 5HT1 antagonists | PFIZER (US) | 1996-05-01 | — | — | CN | claimed |
| EP-0696194-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1994025023-A9 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | — | 1995-10-05 | — | — | WO | claimed |
| WO-1994025023-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1994-11-10 | — | — | WO | claimed |
| JP-8245383-A | — | — | None | — | — | JP | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| WO-1994025023-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1B 8/4885HTR1D 26/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.